Medindia

X

In the Acute Coronary Syndrome Drug Market, the Uptake of Eli Lilly/Daiichi Sankyo's Effient Will Be Constrained by the Widespread Use of Astrazeneca's Brilinta

Friday, February 26, 2010 Heart Disease News J E 4
Advertisement
Effient's Drawbacks Include a High Rate of Bleeding and Lack of Reversibility, According to New Findings from Decision Resources

For more information, contact:

Decision Resources, Inc.

Christopher Comfort

781-296-2597

ccomfort@dresources.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Supelco(R) Introduces Breakthrough in Bioseparatio...
S
Aware, Inc. Joins HIMSS10 Interoperability Showcas...